Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
20.65
+1.16 (5.95%)
At close: Nov 3, 2026, 4:00 PM EST
20.38
-0.27 (-1.32%)
After-hours: Nov 3, 2026, 7:54 PM EST
Company Description
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom.
The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.
The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4.
The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 20, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 465 |
| CEO | Sushil Patel |
Contact Details
Address: 500 Unicorn Park Drive, Suite 303, 3rd Floor Woburn, Massachusetts 01801 United States | |
| Phone | 781 222 9600 |
| Website | replimune.com |
Stock Details
| Ticker Symbol | REPL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001737953 |
| CUSIP Number | 76029N106 |
| ISIN Number | US76029N1063 |
| Employer ID | 82-2082553 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sushil Patel Ph.D. | Chief Executive Officer and Director |
| Emily Luisa Hill | Chief Financial Officer |
| Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Philip Astley-Sparke F.S.A. | Executive Chairman |
| Carolyn Trott | Senior Vice President of Quality Assurance |
| Kari Jeschke | Senior Vice President of Regulatory Affairs |
| Michelle DiNapoli | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 3, 2026 | 144 | Filing |
| Nov 2, 2026 | 144 | Filing |
| Oct 30, 2026 | 144 | Filing |
| Oct 28, 2026 | 144 | Filing |
| Oct 28, 2026 | 10-Q | Quarterly Report |
| Oct 28, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 8-K | Current Report |
| Aug 14, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |